



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 304046 Vitamin C Plus

ARTG entry for Medicine Listed
Sponsor Interclinical Laboratories Pty Ltd
Postal Address PO Box 6474, ALEXANDRIA, NSW, 2015
Australia
ARTG Start Date 7/06/2018
Product Category Medicine
Status Active
Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Vitamin C Plus

Product Type	Single Medicine Product	Effective Date	28/05/2020
--------------	-------------------------	----------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support collagen formation
Maintain/support heat/energy production/thermogenesis
Maintain/support general health and wellbeing
Maintain/support healthy teeth
Maintain/support connective tissue health
Aid/assist/helps connective tissue production/formation
Maintain/support bone health
Aids/assists healthy bone development/growth/building
Maintain/support blood capillary health
Maintain/support blood vessel health
Maintain/support immune system health
Maintain/support healthy immune system function
Aid/assist/helps glucose/sugar/carbohydrate metabolism
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system health
Maintain/support nervous system function
Decrease/reduce/relieve common cold duration
Decrease/reduce/relieve the severity of common cold symptoms
Maintain/support skin health



Australian Government
Department of Health
Therapeutic Goods Administration

Maintain/support wound healing

Indication Requirements

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR
[Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

ascorbic acid 500 mg

manganese (II) glycinate 3.7 mg

Equivalent: manganese 1 mg

Reynoutria japonica root Extract dry concentrate standardised 50 mg

Equivalent: Reynoutria japonica (Dry) 10 g

Rosa canina fruit Extract dry concentrate 60 mg

Equivalent: Rosa canina (Dry) 600 mg

rutoside 100 mg

Other Ingredients (Excipients)

citric acid

hypromellose

magnesium stearate

maltodextrin

microcrystalline cellulose

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.